2024’s Mid-Year Review: FDA-Approved Cardiorenal Metabolic Drugs and Devices
Cardiometabolic Health Congress
JULY 17, 2024
Aprocitentan (Tryvio) Approved: March 20, 2024 Indication: Hypertension in adults Administration: Oral Mechanism: Endothelin A and B receptor antagonist Developer: Idorsia Pharmaceuticals Significance: First and only FDA-approved endothelin receptor antagonist for high blood pressure that remains uncontrolled with existing treatments.
Let's personalize your content